Moderna: 'Our vaccine may have prolonged immunity'.
American pharmaceutical company Moderna today assured that the vaccine it has developed against Covid-19 has the potential to provide long-lasting immunity and that it expects to have 20 million doses ready for distribution in the United States this year.
The company announced that, according to studies by the U.S. National Institute of Allergy and Infectious Diseases, participants in the early phases of the vaccine's clinical trials maintained "high levels of neutralizing antibodies" for three months after the first shot and two months after the second. The study also notes that the vaccine has "the potential to provide long-lasting immunity" to the coronavirus, without causing significant side effects after two months.
EDITORIAL TEAM
Choose the social channel you want to subscribe to